News + Resources

For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans.

Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the unique U.S. life sciences ecosystem, fueling diversity, partnerships and efficiencies among innovative companies of all sizes.

Every day, life sciences innovators discover promising new therapies with the potential to transform our approach to treating life-altering or life-threatening diseases. But what lies between these initial discoveries and an FDA-approved treatment reaching patients is the so-called “valley of death” – the considerable scientific, regulatory and financial hurdles that life sciences companies must overcome to bring their biopharmaceutical breakthroughs to market.

In one of the more challenging investment economies in decades, life science innovators are increasingly forced to face difficult economic headwinds and market demands in their pursuit of breakthrough treatments and cures. 

Following the public comment period on the FTC and DOJ’s proposed merger guidelines, leading antitrust experts and economists expressed significant concerns about the dramatic shift in competition policy that the proposal represents. In a recent panel discussion hosted by AEI, panelists zeroed in on the gaps in the proposed guidelines and the broad impact that they would have on consumers, underscoring the importance of a balanced approach to merger enforcement.

A recent survey by the U.S Chamber of Commerce sheds new light on the flaws of the Federal Trade Commission (FTC) and Department of Justice’s proposed approach to review and enforcement of mergers and acquisitions (M&A).

In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.

In a sharp departure from longstanding precedent, the Federal Trade Commission (FTC) and Department of Justice (DOJ) have proposed substantial changes to the existing guidelines and rules for antitrust enforcement.

In a recent op-ed for Politico, Ankush Khardori, an attorney and former federal prosecutor for the Department of Justice (DOJ), points out the noticeable lack of evidence behind the DOJ and Federal Trade Commissions’ (FTC) proposed merger guidelines.